G. Demetri

发表

High-throughput oncogene mutation profiling in human cancer

S. Gabriel, S. Nelson, M. Meyerson, 2007, Nature Genetics.

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

J. Fletcher, G. Demetri, F. Hodi, 2008, Clinical Cancer Research.

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

T. Jacks, D. Tuveson, J. Fletcher, 2001, Oncogene.

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

G. Demetri, R. DeMatteo, M. Heinrich, 2002, Human pathology.

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

K. Owzar, M. Bertagnolli, J. Fletcher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.

C. Antonescu, G. Demetri, R. Maki, 2010 .

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

C. Antonescu, J. Fletcher, G. Demetri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Major response to imatinib mesylate in KIT-mutated melanoma.

A. D. Van den Abbeele, G. Demetri, F. Hodi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

J. Desai, G. Demetri, P. Larsen, 2006, Annals of Internal Medicine.

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

Steven J. M. Jones, Christopher A. Miller, Richard A. Moore, 2017, Cell.

Soft tissue sarcoma.

G. Demetri, M. Heslin, M. Bui, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

D. Huse, G. Demetri, H. Joensuu, 2007, Clinical drug investigation.

Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

G. Demetri, 2002, European journal of cancer.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

D. Tuveson, G. Demetri, H. Joensuu, 2001, The New England journal of medicine.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

A. D. Van den Abbeele, S. Silverman, D. Tuveson, 2002, The New England journal of medicine.

Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST)

G. Demetri, H. Joensuu, C. Blanke, 2008 .

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

A. D. Van den Abbeele, A. Giobbie-Hurder, K. Flaherty, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level.

G. Demetri, J. Griffin, T. Ernst, 1989, The Journal of biological chemistry.

Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma

A. D. Van den Abbeele, J. Friedberg, G. Demetri, 1999, Cancer.

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.

G. Demetri, M. von Mehren, J. Hamm, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

Wei Zheng, Nathanael S Gray, Katsuhiro Okuda, 2010, Cancer research.

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Jeffrey W. Clark, A. Fischman, G. Demetri, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

G. Demetri, R. Maki, M. von Mehren, 2019, Cancer.

Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

G. Demetri, S. George, J. Morgan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

G. Demetri, A. Huvos, R. Maki, 2003, Cancer.

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

G. Demetri, R. Maki, D. Ryan, 2002, Cancer Chemotherapy and Pharmacology.

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

J. Manola, G. Demetri, R. Maki, 2002, The oncologist.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

J. Blay, G. Demetri, R. Maki, 2012, European journal of cancer.

Hematopoietic growth factors: current knowledge, future prospects.

G. Demetri, 1992, Current problems in cancer.

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs

G. Demetri, L. Burke, Martha Donoghue, 2020, Clinical Cancer Research.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

G. Demetri, C. Cleeland, D. Cella, 2002, Cancer.

CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans

R. Coffman, D. Neuberg, P. Wen, 2008, Clinical Cancer Research.

Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival.

J. Fletcher, G. Demetri, S. Singer, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence-Based Use of Hematopoietic Growth Factors for Optimal Supportive Care of Patients with Cancer

G. Demetri, 2006 .

Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec

G. Demetri, K. Ganjoo, Shreyaskumar R Patel, 2009, Leukemia & lymphoma.

Soft tissue sarcoma clinical practice guidelines in oncology.

D. Ettinger, G. Demetri, M. Heslin, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Evidence-Based Use of Hematopoietic Cytokines in Clinical Oncology

G. Demetri, 1999 .

The biology of GM-CSF: regulation of production and interaction with its receptor.

G. Demetri, S. Cannistra, J. Griffin, 1990, International journal of cell cloning.

Tissue factor gene expression in acute myeloblastic leukemia.

G. Demetri, J. Griffin, W. Konigsberg, 1989, Thrombosis research.

NCCN Sarcoma Practice Guidelines

G. Demetri, E. Casper, R. Pollock, 1998 .

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

G. Demetri, S. George, J. Morgan, 2015, Cancer.

Angiogenesis and Angiogenesis Inhibition in Sarcomas

G. Demetri, S. DuBois, 2008 .

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

G. Demetri, K. Papadopoulos, A. Patnaik, 2018, BMC Cancer.

Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome

S. Armstrong, J. Fletcher, G. Demetri, 2018, Proceedings of the National Academy of Sciences.

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST

G. Demetri, H. Guchelaar, H. Gelderblom, 2014, BMC Cancer.

2000 U pdate o f R ecommendations f or t he U se o f Hematopoietic C olony-Stimulati ng F actors: E vidence- Based, C linical P ractice G uidelines

Thomas J. Smith, J. Armitage, G. Demetri, 2000 .

Multimodality treatment of mesenteric desmoid tumours.

M. Bertagnolli, G. Demetri, C. Raut, 2008, European journal of cancer.

Update on new diagnostic and therapeutic approaches for sarcomas.

G. Demetri, P. Dileo, 2005, Clinical advances in hematology & oncology : H&O.

A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update

J. Blay, G. Demetri, M. Debiec‐Rychter, 2007 .

Prognostic Factors Predictive of Survival for Truncal and Retroperitoneal Soft‐Tissue Sarcoma

G. Demetri, T. Eberlein, J. Corson, 1995, Annals of surgery.

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

G. Demetri, W. Tap, Q. Wang, 2012, American journal of hypertension.

Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines

Stephen A. Allsop, D. Neuberg, M. Mihm, 2015, Clinical Cancer Research.

Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM.

A. D. Van den Abbeele, G. Demetri, J. Kovarik, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST)

J. Manola, G. Demetri, R. Badawi, 2005 .

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Robin L. Jones, B. Monk, G. Demetri, 2017, Gynecologic oncology.

Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

J. Goldblum, G. Demetri, M. von Mehren, 2012, Cancer.

Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate

J. Manola, M. Bertagnolli, G. Demetri, 2010, Annals of Surgical Oncology.

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

A. D. Van den Abbeele, G. Demetri, J. Yap, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

M. Kris, G. Demetri, R. Herbst, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST

G. Demetri, M. Heinrich, P. Casali, 2005 .

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.

G. Demetri, A. Farago, 2020, Future oncology.

Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT

M. Bertagnolli, J. Fletcher, G. Demetri, 2005 .

The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesothelioma

Amy Bernard, D. Housman, M. Minden, 1993, Nature Genetics.

The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments

J. Blay, G. Demetri, A. Le Cesne, 2020, Expert review of anticancer therapy.

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

J. Fletcher, G. Demetri, M. Heinrich, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal stromal tumors (GISTs)

S. Ashley, G. Demetri, Mandeep S. Saund, 2004, Current opinion in gastroenterology.

Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes

J. Fletcher, G. Demetri, P. Cin, 2005, Oncogene.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

J. Blay, G. Demetri, A. Cesne, 2019, BMC Cancer.

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin

Robin L. Jones, G. Demetri, R. Maki, 2019, Cancer.

Resumption of Imatinib dosing to control metastatic Gastrointestinal Stromal Tumors (GIST) after failure of Imatinib and Sunitinib: Results of a randomised, placebo-controlled, phase 3 trial (RIGHT)

G. Demetri, J. Jagannathan, B. Nam, 2015 .

Response to Chemotherapy and Predictors of Survival in Adult Rhabdomyosarcoma

G. Demetri, S. Singer, E. Baldini, 2001, Annals of surgery.

Long-Term O utcomes A fter F unction-Sparing S urgery Without R adiotherapy f or S oft T issue S arcoma of t he E xtremities a nd T runk

J. Manola, G. Demetri, S. Singer, 1999 .

The Emergence of Peripheral Blood Progenitor Cells to Support Intensive Chemotherapy for Patients with Breast Cancer

G. Demetri, 1996, Pharmacotherapy.

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

J. Niloff, K. Anderson, G. Demetri, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloid growth factors clinical practice guidelines in oncology.

J. Armitage, G. Demetri, G. Lyman, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Imaging features of bone metastases in patients with gastrointestinal stromal tumors.

S. Silverman, G. Demetri, J. Glickman, 2012, Diagnostic and interventional radiology.

Clinical Applications of Cytokines and Growth Factors

G. Demetri, J. Wingard, 1999, Developments in Oncology.

Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium.

G. Demetri, F. Hildebrandt, M. Pollak, 2016, Seminars in nephrology.

Stem cell factor is a potent synergistic factor in hematopoiesis.

G. Demetri, J. Crawford, M. Gordon, 1994, Oncology.

Hematologic effects of recombinant human Interleukin-6 (rhIL-6) in sarcoma patients receiving maid chemotherapy: phase I trial

G. Demetri, R. Bukowski, M. Gordon, 1994 .

Cardiotoxicity associated with sunitinib – Authors' reply

G. Demetri, M. Chen, T. Force, 2008, The Lancet.

mesothelial cells and human malignant mesothelioma cells lines in vitro Expression of colony-stimulating factor genes by normal human

G. Demetri, J. Griffin, J. Rheinwald, 2011 .

Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma

W. Fiers, G. Demetri, D. Kufe, 1989, The Journal of experimental medicine.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Andrew L. Kung, Matthew D. Wilkerson, Michael D. Cameron, 2012, Nature.

Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.

K. Anderson, G. Demetri, A. Freedman, 1989, Journal of Immunology.

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

C. Paweletz, V. Velculescu, J. Fletcher, 2019, Clinical Cancer Research.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation

M. van de Rijn, M. Ladanyi, C. Antonescu, 2017, Nature Communications.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

GIST 1, Chemotherapy 0, with a Brand New Hitter Up Next

G. Demetri, 2002, Cancer investigation.

Short KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors

J. Fletcher, G. Demetri, S. Singer, 2000 .

Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte‐colony‐stimulating factor: implications for yield of hematopoietic progenitor cell collections

G. Demetri, C. Wheeler, L. Ayash, 1996, Transfusion.

NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.

G. Demetri, F. Fossella, D. Gershenson, 1996, Oncology.

A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.

G. Demetri, D. Kufe, D. Spriggs, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Troglitazone, an Activator of the PPARγ Receptor, in Patients with Chemotherapy‐Resistant Metastatic Colorectal Cancer

B. Spiegelman, G. Demetri, N. Sharpless, 2002 .

Clinical presentation and management of mTOR inhibitor-associated stomatitis.

G. Demetri, S. George, S. Sonis, 2011, Oral oncology.

Pharmacologic treatment options in patients with thrombocytopenia.

G. Demetri, 2000, Seminars in hematology.

Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial

J. Blay, G. Demetri, A. Tolcher, 2007 .

Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248

J. Desai, G. Demetri, J. Heymach, 2005 .

Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.

G. Demetri, R. Motzer, T. Suter, 2014, European journal of cancer.

Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.

P. Kantoff, G. Demetri, C. Bokemeyer, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myelosuppression and "conventional" chemotherapy: what price, what benefit?

G. Demetri, G. Canellos, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

G. Demetri, J. Ware, P. LoRusso, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

Yan Zhang, Mark R. Emmett, Alan G. Marshall, 2009, Proceedings of the National Academy of Sciences.

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

Jaegil Kim, G. Demetri, S. Grupp, 2022, Nature Communications.

Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.

G. Demetri, J. Gabrilove, J. Glaspy, 2002, Clinical breast cancer.

Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.

G. Demetri, J. Glaspy, L. Degos, 2002, The oncologist.

Cancer- and treatment-related anemia: Clinical Practice Guidelines in Oncology

M. Millenson, G. Demetri, C. Cleeland, 2005 .

Cancer- and treatment-related anemia.

M. Millenson, G. Demetri, C. Cleeland, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, J. Manola, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.

A. D. Van den Abbeele, J. Manola, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance.

G. Demetri, J. Verweij, P. Casali, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

A. D. Van den Abbeele, J. Manola, J. Desai, 2004, Clinical Cancer Research.

Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST) – early results of RTOG 0132

G. Demetri, B. Eisenberg, M. Heinrich, 2011 .

Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas.

J. Blay, G. Demetri, F. Grosso, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical benefits of epoetin alfa therapy in patients with lung cancer.

G. Demetri, J. Gabrilove, J. Crawford, 2002, Clinical lung cancer.

Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST

J. Blay, G. Demetri, A. Cesne, 2007 .

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

G. Demetri, J. Bruix, A. Grothey, 2021, Cancer Management and Research.

Chemotherapy and neutropenia.

G. Demetri, S. Kim, 1996, Hematology/oncology clinics of North America.

Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail?

G. Demetri, J. Griffin, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

223 POSTER Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation

G. Demetri, J. Ware, P. LoRusso, 2008 .

3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS)

G. Demetri, R. Maki, J. Hamm, 2015 .

A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Robin L. Jones, G. Demetri, H. Tawbi, 2015 .

Activity of larotrectinib in patients with TRK fusion GI malignancies.

A. Drilon, G. Demetri, D. Hong, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Robin L. Jones, G. Demetri, H. Tawbi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST.

J. Blay, G. Demetri, S. George, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial.

G. Demetri, H. Hurwitz, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase 3 SAR-3007 study

Robin L. Jones, B. Monk, G. Demetri, 2016 .

Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.

G. Demetri, F. Hodi, G. Shapiro, 2016 .

Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors

J. Manola, G. Demetri, M. Nucci, 2014, Cancer.

1138 POSTER Neutropenia as a Biomarker of Sunitinib Efficacy in Patients (Pts) With Gastrointestinal Stromal Tumour (GIST)

G. Demetri, S. George, M. Mehren, 2011 .

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

G. Demetri, R. Maki, G. Schwartz, 2008 .

Markers of angiogenesis and clinical features in patients with sarcoma

G. Demetri, S. DuBois, 2007, Cancer.

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Omar H. Butt, Alokkumar Jha, M. Bonnen, 2020, Cancer Cell.

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

C. Antonescu, M. McCarter, G. Demetri, 2012, Journal of the American College of Surgeons.

Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.

J. Aster, G. Demetri, D. Kufe, 1994, Leukemia research.

Leiomyosarcoma of the Inferior Vena Cava: Survival After Aggressive Management

M. Bertagnolli, G. Demetri, C. Raut, 2007, Annals of Surgical Oncology.

Dermatofibrosarcoma protuberans case report: when drug therapy can obviate the need for surgery

G. Demetri, S. George, 2007 .

bone marrow transplantation for lymphoid malignancies granulocyte-macrophage colony-stimulating factor after autologous Long-term follow-up of a phase III study of recombinant human

D. Neuberg, G. Demetri, J. Nemunaitis, 2011 .

Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.

P. Bierman, J. Vose, D. Neuberg, 1993, Blood.

Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors

G. Demetri, P. Richardson, A. Elias, 1998, Cancer.

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-g ligand troglitazone in patients with liposarcoma (nuclear receptorsysarcomaydrug developmentyoncologyyantineoplastic)

G. Demetri, S. Singer, P. Sarraf, 1999 .

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours

G. Demetri, H. Gelderblom, A. Cleton, 2019, British journal of clinical pharmacology.

Malignant Epithelioid Angiomyolipoma (`Sarcoma Ex Angiomyolipoma') of the Kidney: A Case Report and Review of the Literature

G. Demetri, C. Fletcher, E. Cibas, 2001, The American journal of surgical pathology.

Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

G. Demetri, R. Doebele, R. Dziadziuszko, 2019, Annals of Oncology.

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

A. Drilon, G. Demetri, M. Ahn, 2021, ESMO open.

Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).

G. Demetri, Yoon-Koo Kang, B. Nam, 2016, European journal of cancer.

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

G. Demetri, J. Ware, G. Shapiro, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.

J. Armitage, J. George, G. Demetri, 2004, The American journal of medicine.

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

J. Fletcher, G. Demetri, W. Tap, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST

G. Demetri, J. Verweij, P. Casali, 2007 .

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

J. Manola, G. Demetri, G. Shapiro, 2010, Clinical Cancer Research.

Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor

G. Demetri, A. Conley, V. Trinh, 2019, Journal of Immunotherapy for Cancer.

Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments.

Robin L. Jones, Andrea Hayes, J. Blay, 2022, Cancer treatment reviews.

Effect of recombinant human interleukin‐3 on haematological recovery from chemotherapy‐induced myelosuppression

L. Kalish, G. Demetri, T. Lynch, 1994, British journal of haematology.

Impact off Hematopoietic Growth Factors on the Management of Small-Cell Lung Cancer

G. Demetri, 1993 .

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.

A. D. Van den Abbeele, G. Demetri, B. Eisenberg, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

J. Blay, G. Demetri, A. Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

J. Blay, G. Demetri, A. Tolcher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial

G. Demetri, S. George, J. Morgan, 2007 .

Measurement of interstitial fluid pressure (IFP) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948).

R. Jain, Y. Boucher, G. Demetri, 2010 .

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

J. Fletcher, G. Demetri, S. Bauer, 2006, Cancer research.

KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies

M. Bertagnolli, J. Fletcher, G. Demetri, 2005 .

Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions.

A. D. Van den Abbeele, S. Silverman, K. Tuncali, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

G. Demetri, F. Haluska, S. Sonis, 2009, Cancer.

Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST

Sinem K. Saka, S. Gygi, M. Bertagnolli, 2022, British Journal of Cancer.

O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)

A. Drilon, G. Demetri, R. Doebele, 2020 .

Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.

J. Desai, G. Demetri, 2005, Best practice & research. Clinical haematology.

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

G. Demetri, A. Elias, 1995, Hematology/oncology clinics of North America.

In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).

J. Fletcher, G. Demetri, C. Raut, 2013 .

Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET

G. Demetri, J. Yap, R. Maki, 2008 .

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

G. Demetri, A. Saven, J. Rigas, 2001, British Journal of Cancer.

Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation

G. Demetri, A. Elias, K. Antman, 1994, British journal of haematology.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Thomas J. Smith, Gary H Lyman, Thomas J Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulocyte colony-stimulating factor and its receptor.

G. Demetri, J. Griffin, 1991, Blood.

Hematopoietic growth factors.

G. Demetri, 1995, Current opinion in hematology.

Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy.

G. Demetri, 1995, Chest.

Changes in Tc‐99m radionuclide bone scan images and peripheralizatioin of marrow hematopoetic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose‐intensified chemotherapy for breast cancer

G. Demetri, R. Salgia, W. Kaplan, 1994, Cancer.

In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells.

G. Demetri, S. Cannistra, J. Griffin, 1988, Experimental hematology.

7501 ORAL Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing

J. Blay, G. Demetri, A. Cesne, 2007 .

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

Robin L. Jones, G. Demetri, O. Mir, 2020, The Lancet. Oncology.

Soft tissue sarcoma (STS): Challenges in identification, treatment patterns, and costs of disease management in the U.S.

M. Neary, G. Demetri, M. Duh, 2008 .

Real‐world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

G. Demetri, M. Gounder, B. V. Van Tine, 2020, Cancer.

Impact of hematopoietic growth factors on the management of small-cell lung cancer.

G. Demetri, 1993, Chest.

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

J. Blay, G. Demetri, E. Van Cutsem, 2014, The oncologist.

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications

G. Demetri, A. Italiano, Ying Huang, 2020, Cancers.

Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan

G. Demetri, A. Iagaru, C. Bedrosian, 2005 .

A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update

J. Blay, J. Fletcher, G. Demetri, 2005 .

Myeloid growth factors. Clinical practice guidelines in oncology.

J. Armitage, G. Demetri, G. Lyman, 2007, The Journal of the National Comprehensive Cancer Network.

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001.

J. Krauss, G. Demetri, R. Doebele, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ecdysteroid Hormone Effects on a Drosophila Cell Line

G. Demetri, C. Savakis, L. Cherbas, 1980 .

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Alokkumar Jha, M. Bonnen, S. Shete, 2020, The Lancet.

Cancer as a Paradigm for Translational and Clinical Biomedical Research

G. Demetri, C. Serrano, 2017 .

Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.

E. Winer, G. Hortobagyi, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Marc Ladanyi, Jeffrey W. Clark, M. Ladanyi, 2010, The New England journal of medicine.

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

c‐Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas

M. Loda, J. Fletcher, G. Demetri, 2014, The Journal of pathology.

Soft Tissue Sarcoma

D. Ettinger, G. Demetri, M. Heslin, 1999 .

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

J. Blay, G. Demetri, A. Cesne, 2012, The Lancet.

SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters

Wai Lim Ku, R. Irizarry, J. Ranish, 2017, Nature Genetics.

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

G. Demetri, S. Grupp, B. V. Van Tine, 2019, Journal of Immunotherapy for Cancer.

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo

G. Demetri, S. Galli, A. Dvorak, 1996, The Journal of experimental medicine.

Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

S. Carter, G. Freeman, E. V. Van Allen, 2017, Immunity.

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

Xin Huang, Patrick Schöffski, G. Demetri, 2009, Clinical Cancer Research.

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

G. Demetri, H. Joensuu, M. Heinrich, 2004 .

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

C. J. Chen, D. Tuveson, J. Fletcher, 2001, Cancer research.

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

J. Fletcher, G. Demetri, S. Singer, 2000, The American journal of pathology.

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Funda Meric-Bernstam, Ryma Benayed, Marc Ladanyi, 2018, The New England journal of medicine.

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David M. Hyman, David S. Hong, Alberto S. Pappo, 2017 .

Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence

J. Fletcher, G. Demetri, W. Ou, 2019, Oncogene.

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma

G. Getz, S. Carter, L. Garraway, 2019, Clinical Cancer Research.

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Robin L. Jones, J. Blay, J. Fletcher, 2007, The Lancet. Oncology.

Soft tissue sarcomas of adults: state of the translational science.

P. Meltzer, M. Ladanyi, J. Fletcher, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy

A. B. Hassan, G. Demetri, T. van Wezel, 2013, Clinical Cancer Research.

Cancer Therapy : Preclinical Functional Pro fi ling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identi fi es Pathways for Rational Targeted Therapy

A. B. Hassan, G. Demetri, A. Wagner, 2013 .

PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

Samuel Singer, Jonathan A. Fletcher, J. Fletcher, 2003, Science.

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

J. Fletcher, G. Demetri, R. Nakayama, 2016, Oncotarget.

Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.

M. van de Rijn, J. Fletcher, G. Demetri, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)

J. Fletcher, G. Demetri, S. Singer, 2004, Oncogene.

Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs

M. van de Rijn, C. Antonescu, J. Fletcher, 2014, Nature Genetics.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

J. Blay, Ruey-min Lee, G. Demetri, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aberrant AKT activation drives well-differentiated liposarcoma

A. Look, J. Fletcher, G. Demetri, 2011, Proceedings of the National Academy of Sciences.

Protein Kinase C θ (PKCθ) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs)

J. Fletcher, G. Demetri, M. Heinrich, 2004, Cancer Research.

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

B. Spiegelman, G. Demetri, S. Singer, 1999, Proceedings of the National Academy of Sciences of the United States of America.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

J. Blay, G. Demetri, J. Verweij, 2012, European journal of cancer.

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

G. Demetri, R. Dummer, S. Ferretti, 2021, British Journal of Cancer.

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

J. Blay, G. Demetri, M. von Mehren, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

J. Blay, G. Demetri, B. Bui, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.

M Mazumdar, G. Demetri, M. Mazumdar, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

International expert opinion on patient-tailored management of soft tissue sarcomas.

S. Sleijfer, J. Blay, G. Demetri, 2014, European journal of cancer.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

C. Antonescu, M. McCarter, K. Owzar, 2009, The Lancet.

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

A. D. Van den Abbeele, G. Demetri, P. Pedrazzoli, 2009, Pediatric blood & cancer.

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

J. Fletcher, G. Demetri, S. Singer, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

J. Blay, G. Demetri, Yoon-Koo Kang, 2015, The Lancet. Oncology.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

J. Blay, G. Demetri, A. Cesne, 2013, The Lancet.

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

P Reichardt, J. Blay, G. Demetri, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

J. Blay, G. Demetri, H. Borghaei, 2009, Clinical Cancer Research.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Xin Huang, J. Desai, G. Demetri, 2006, The Lancet.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

J. Blay, G. Demetri, A. Cesne, 2016, The Lancet.

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1

P. Sorger, Jia-Ren Lin, M. Bertagnolli, 2020, JCO precision oncology.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

A. Drilon, J. Krauss, G. Demetri, 2019, The Lancet. Oncology.

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

C. Antonescu, J. Desai, J. Fletcher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo

G. Demetri, Alice T. Loo, A. Kung, 2014, Molecular Cancer Therapeutics.

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

J. Blay, G. Demetri, F. Grosso, 2013, British Journal of Cancer.

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

J. Blay, G. Demetri, A. Cesne, 2012, Investigational New Drugs.

Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide.

J. Blay, G. Demetri, M. von Mehren, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

J. Manola, G. Demetri, R. Maki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

G. Demetri, A. Racine, H. Joensuu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research

E. Lander, T. Golub, G. Demetri, 2019, Nature Medicine.

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

B. Spiegelman, P. Kantoff, G. Demetri, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.

G. Demetri, G. Gordon, E. Rowinsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.

G. Demetri, 2011, Seminars in oncology.

Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.

G. Demetri, J. Griffin, J. Rheinwald, 1989, Blood.

Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.

G. Demetri, J. Marshall, M. Pishvaian, 2010 .

Small Molecule Therapeutics Antiproliferative Effects of CDK 4 / 6 Inhibition in CDK 4-Ampli fi ed Human Liposarcoma In Vitro and In Vivo

G. Demetri, Alice T. Loo, A. Kung, 2014 .

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

J. Fletcher, G. Demetri, S. Bauer, 2007, Oncogene.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

J. Blay, G. Demetri, T. Clackson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular basis for sunitinib efficacy and future clinical development

G. Demetri, E. Raymond, S. Faivre, 2007, Nature Reviews Drug Discovery.

Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.

G. Demetri, J. Griffin, J. Rheinwald, 1990, The Journal of clinical investigation.

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

G. Demetri, S. Gwyther, M. Leach, 2013, Clinical Cancer Research.

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Jessica M. Silvaggi, B. Spiegelman, R. Weissleder, 2008, Clinical Cancer Research.

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.

J. Desai, G. Demetri, A. Tolcher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma

G. Demetri, M. Muto, S. George, 2014, Cancer.

Prognostic V alue o f KIT Mutation T ype, M itotic A ctivity, and H istologic S ubtype i n G astrointestinal S tromal Tumors

J. Fletcher, G. Demetri, S. Singer, 2002 .

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Carlos L Arteaga, G. Demetri, B. Druker, 2015, Circulation.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

G. Demetri, R. Motzer, B. Houk, 2010, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

Qian Wang, A. D. Van den Abbeele, Edwin Choy, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx).

A. D. Van den Abbeele, J. Manola, G. Demetri, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

G. Parmigiani, G. Demetri, C. Tomasetti, 2013, F1000Research.

Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor.

J. Sklar, G. Demetri, H. Grier, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

J. Blay, G. Demetri, P. Stephenson, 2009, European journal of cancer.

Advances and controversies in the management of soft tissue sarcomas.

J. Blay, G. Demetri, P. Casali, 2017, Future oncology.

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009, Clinical Cancer Research.

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs

William A. Flavahan, Sarah E. Johnstone, B. Bernstein, 2019, Nature.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

G. Demetri, B. Eisenberg, M. Heinrich, 2009, Journal of surgical oncology.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

G. Demetri, 2001, Seminars in oncology.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

M. Bertagnolli, J. Fletcher, G. Demetri, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.

G. Demetri, S. George, J. Morgan, 2019, European journal of cancer.

Targeted approaches for the treatment of thrombocytopenia.

G. Demetri, G D Demetri, 2001, The oncologist.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

J. Crowley, G. Demetri, R. Maki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of soft-tissue sarcomas: an overview and update.

G. Demetri, S. Singer, E. Baldini, 2000, The Lancet. Oncology.

Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk.

J. Manola, G. Demetri, S. Singer, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes

S. Armstrong, Changyu Fan, G. Demetri, 2020, Molecular Cancer Research.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Blay, G. Demetri, A. Tolcher, 2015, The Lancet. Oncology.

Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).

J. Blay, G. Demetri, A. Italiano, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009 .

Management of malignant gastrointestinal stromal tumours.

G. Demetri, H. Joensuu, P. Roberts, 2002, The Lancet. Oncology.

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors

D. Hibar, G. Demetri, O. Humblet, 2022, PloS one.

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Rachel B. Keller, Jeffrey W. Clark, M. Meyerson, 2021, Clinical Cancer Research.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

J. Fletcher, G. Demetri, H. Joensuu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy: Clinical A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

J. Blay, G. Demetri, H. Borghaei, 2009 .

Systemic treatment of patients with gastrointestinal stromal tumor: Current status and future opportunities

G. Demetri, H. Joensuu, 2008 .

Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).

J. Blay, G. Demetri, Yoon-Koo Kang, 2013 .

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

G. Demetri, I. Ray-Coquard, P. Reichardt, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

J. Blay, M. van Glabbeke, G. Demetri, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.

Varun Garg, G. Demetri, E. Ette, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.

G. Demetri, E. Ette, V. Bramwell, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

G. Demetri, S. George, D. Cohen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

G. Demetri, J. Baselga, D. Haber, 2014, BMC Cancer.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

A. D. Van den Abbeele, J. Blay, D. Ettinger, 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

C. Antonescu, G. Demetri, C. Raut, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.

H. Ji, L. Chirieac, Kwok-Kin Wong, 2007, The Journal of clinical investigation.

HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor

S. Armstrong, M. van de Rijn, P. Sorger, 2021, Clinical Cancer Research.

KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance

J. Fletcher, G. Demetri, C. Fletcher, 2007, Oncogene.

Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).

J. Fletcher, G. Demetri, M. Heinrich, 2004, Cancer research.

Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar ( VX-710 ) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma 1

G. Demetri, E. Ette, V. Bramwell, 2002 .

Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

K. Flaherty, G. Demetri, J. Verweij, 2013, European Journal of Cancer.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

J. Blay, G. Demetri, Yoon-Koo Kang, 2016, BMC Cancer.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

J. Blay, J. Fletcher, G. Demetri, 2015, The oncologist.

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

G. Demetri, H. Hurwitz, Yoon-Koo Kang, 2015, Cancer.

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

J. Manola, G. Demetri, A. Shinagare, 2014, European journal of cancer.

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

G. Demetri, Yoon-Koo Kang, J. Jagannathan, 2013, The Lancet. Oncology.

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

David Goldstein, Serge Leyvraz, Patrick Schöffski, 2012, Clinical Cancer Research.

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

C. Antonescu, M. O'sullivan, J. Fletcher, 2010, Proceedings of the National Academy of Sciences.

Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification

J. Barretina, J. Fletcher, G. Demetri, 2010, International journal of cancer.

Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.

M. Washington, J. Goldblum, G. Demetri, 2010, Archives of pathology & laboratory medicine.

12 – Sarcomas of Soft Tissue and Bone and Gastrointestinal Stromal Tumors

G. Demetri, N. Joste, S. George, 2010 .

A phase I – II study of everolimus ( RAD 001 ) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

G. Demetri, I. Ray-Coquard, P. Reichardt, 2010 .

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

A. D. Van den Abbeele, C. Antonescu, J. Fletcher, 2009, Clinical Cancer Research.

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

David Zurakowski, Frederick J Schoen, Flavia Cassiola, 2007, The Lancet.

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.

G. Demetri, 2007, The Journal of clinical investigation.

Advances in the treatment of gastrointestinal stromal tumours.

I Judson, G. Demetri, I. Judson, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

JNCCN NCCN Task Force Report : Optimal Management of Patients with Gastrointestinal Stromal Tumor ( GIST ) — Update of the NCCN Clinical Practice Guidelines

J. Blay, D. Ettinger, G. Demetri, 2007 .

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.

C. Antonescu, J. Fletcher, G. Demetri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy

Ming-Hui Chen, J. Desai, G. Demetri, 2005 .

Polyclonal Resistance in Gastrointestinal Stromal Tumor Treated with Sequential Kinase Inhibitors

G. Demetri, A. Dobrovic, G. McArthur, 2006, Clinical Cancer Research.

Kinase M utations a nd I matinib R esponse i n P atients W ith Metastatic G astrointestinal S tromal T umor

J. Fletcher, G. Demetri, S. Singer, 2003 .

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial

C. Antonescu, M. McCarter, K. Owzar, 2013, Annals of surgery.

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

J. Desai, M. Bertagnolli, G. Demetri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

M. Kris, G. Demetri, D. Cella, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

C. Antonescu, G. Demetri, A. Ligon, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

209 – Sarcomas of Soft Tissue and Bone, and Other Neoplasms of Connective Tissues

G. Demetri, 2012 .

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

G. Demetri, P. Sharma, A. Tolcher, 2021, Clinical Cancer Research.

1205 A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours

G. Demetri, J. Ware, P. LoRusso, 2009 .

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors

G. Demetri, J. Ware, P. LoRusso, 2009 .

The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.

G. Demetri, J. Griffin, C. Civin, 1990, Blood.

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

D. Berry, E. Winer, C. Hudis, 2008, Cancer treatment reviews.

Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer

D. Berry, R. Schilsky, S. Martino, 2003 .

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer

G. Demetri, P. Richardson, R. Joyce, 2001, Bone Marrow Transplantation.

Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins

D. Adler, C. Disteche, G. Demetri, 1989, The Journal of experimental medicine.

Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy

G. Demetri, 2001, British Journal of Cancer.

Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

David M. Thomas, Kevin B. Jones, Robin L. Jones, 2021, Cancer.

Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas

G. Demetri, S. Stacchiotti, 2021, Oncology.

Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505

J. Goldblum, G. Demetri, C. Rankin, 2008 .

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Robin L. Jones, J. Blay, G. Demetri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).

Robin L. Jones, G. Demetri, A. Italiano, 2017 .

Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).

Robin L. Jones, G. Demetri, T. Chen, 2019, Journal of Clinical Oncology.

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.

G. Demetri, K. Ganjoo, S. George, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033

J. Crowley, K. Owzar, J. Fletcher, 2017, JAMA oncology.

Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors

A. D. Van den Abbeele, J. Manola, J. Desai, 2007, Clinical Cancer Research.

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

G. Demetri, E. Ben Ami, 2016, Expert opinion on drug safety.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

C. Antonescu, M. McCarter, K. Owzar, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.

A. D. Van den Abbeele, Ramsey D Badawi, Annick D Van den Abbeele, 2007, AJR. American journal of roentgenology.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

J. Desai, G. Demetri, J. Verweij, 2006, The Lancet.

Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.

A. D. Van den Abbeele, J. Desai, G. Demetri, 2005, Radiology.

Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.

G. Demetri, M. Amand, J. Griffin, 2005, Clinical journal of oncology nursing.

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.

G. Demetri, 2002, Hematology/oncology clinics of North America.

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

G. Demetri, H. Joensuu, M. Heinrich, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.

J. Blay, G. Demetri, J. Radford, 2010 .

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

J. Manola, G. Demetri, R. Maki, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

J. Fletcher, G. Demetri, R. Herrmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments

M. Neary, G. Demetri, M. Duh, 2015, BMC Cancer.

High rates of histopathologic discordance in sarcoma with implications for clinical care.

G. Demetri, C. Raut, E. Baldini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

G. Demetri, K. Papadopoulos, A. Patnaik, 2018, BMC Cancer.

Derivation and validation of a risk classification tree for patients with synovial sarcoma

G. Demetri, J. Hornick, Natalie B Collins, 2022, Cancer medicine.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

G. Demetri, P. LoRusso, L. Dirix, 2018, Investigational New Drugs.

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

G. Demetri, Tanmay Parekh, R. Maki, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950).

J. Blay, G. Demetri, A. Italiano, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer

E. Winer, G. Hortobagyi, G. Demetri, 2003 .

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

J. Blay, G. Demetri, Melissa L. Johnson, 2021 .

298 Final analysis of the phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)

G. Demetri, V. Chiou, W. Chow, 2020 .

Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy

J. Manola, F. Rybicki, S. Silverman, 2005, European Radiology.

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Heikki Joensuu, Richard Herrmann, J. Fletcher, 2008, Clinical Cancer Research.

Stem Cell Factor

G. Demetri, G. Tricot, C. Begley, 2000 .

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

I Judson, J Verweij, J. Blay, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL).

G. Demetri, A. Le Cesne, P. Hohenberger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report.

G. Demetri, R. Salgia, W. Kaplan, 1994, Cancer.

Myeloid growth factors.

J. Armitage, G. Demetri, G. Lyman, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome.

G. Demetri, S. Singer, E. Baldini, 1999, Annals of surgery.

Reply to W.F. Pirl et al

G. Demetri, S. Block, S. George, 2009 .

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

G. Demetri, R. Herbst, A. Rashid, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors

D. Root, J. Fletcher, G. Demetri, 2014, Oncogene.

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

G. Demetri, S. George, J. Morgan, 2013, Clinical Cancer Research.

Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS).

J. Blay, G. Demetri, A. Italiano, 2013 .

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors

G. Demetri, N. Senzer, I. Judson, 2012, Cancer.

A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies

G. Demetri, J. Marshall, M. Pishvaian, 2012, Cancer.

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas

J. Desai, G. Demetri, D. Zahrieh, 2007, Cancer.

Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-In-Class Antibody-Drug Conjugate.

G. Demetri, A. Ochiai, S. George, 2021, Cancer discovery.

E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor

M. Gut, J. Barretina, J. Fletcher, 2021, Oncogene.

High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.

G. Demetri, 1996, Seminars in oncology.

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs

B. Bernstein, Y. Drier, G. Demetri, 2019, Nature.

Effi cacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib ( GRID ) : an international , multicentre , randomised , placebo-controlled , phase 3 trial

J. Blay, G. Demetri, A. Cesne, 2013 .

Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.

S. Sleijfer, G. Demetri, H. Joensuu, 2009, Seminars in oncology.

Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs)

M. Bertagnolli, J. Fletcher, G. Demetri, 2007 .

Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.

G. Demetri, K. Junge, L. Baker, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evolution of the International Sarcoma Community: A Personal Perspective

G. Demetri, 2018, Oncology.

Ecdysteroid-inducible polypeptides in a Drosophila cell line

G. Demetri, C. Savakis, P. Cherbas, 1980, Cell.

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

G. Demetri, Q. Zhang, B. Eisenberg, 2012, Annals of Surgical Oncology.

Dynamic Infrared Imaging of Newly Diagnosed Malignant Lymphoma Compared with Gallium-67 and Fluorine-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography

G. Demetri, G Demetri, M J Janicek, 2003, Technology in cancer research & treatment.

Small molecule tyrosine kinase inhibitor and depression.

G. Demetri, S. Block, S. George, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST)

G. Demetri, P. Rutkowski, P. Hohenberger, 2014 .

Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) : Subgroup analysis of outcomes based on pretreatment characteristics

J. Blay, G. Demetri, A. Cesne, 2013 .

Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update

J. Blay, G. Demetri, A. Cesne, 2012 .

Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

Patrick Schöffski, Paolo G. Casali, G. Demetri, 2008 .

Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors

J. Fletcher, G. Demetri, C. Fletcher, 2008, Oncogene.

Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations.

G. Demetri, K. Antman, 1992, Seminars in oncology.

Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.

S. Armstrong, G. Demetri, J. Bradner, 2019, Cancer research.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

Abstract 5181: Therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumor (GIST), with DS-6157a, an antibody-drug conjugate (ADC)

G. Demetri, A. Ochiai, S. George, 2020 .

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

G. Demetri, R. Riedel, M. Heinrich, 2016, European journal of cancer.

Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations

E. Winer, K. Emmons, G. Demetri, 2007, Journal of Cancer Education.

Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret.

E. Winer, K. Emmons, G. Demetri, 2006, Patient education and counseling.

Diagnosis in oncology. Askin tumor.

G. Demetri, S. Singer, J. Amatruda, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST).

J. Hodgson, J. Fletcher, G. Demetri, 2015 .

Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.

J. Blay, G. Demetri, A. Cesne, 2013 .

Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)

J. Desai, J. Fletcher, G. Demetri, 2005 .

Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950).

G. Demetri, A. Italiano, M. Gounder, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial

G. Demetri, T. Nishida, T. Kanda, 2015, International Journal of Clinical Oncology.

Abstract LB-174: Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy.

G. Demetri, J. Baselga, D. Haber, 2013 .

A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.

G. Demetri, M. Gounder, S. Blakemore, 2016 .

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.

B. Spiegelman, G. Demetri, N. Sharpless, 2002, Cancer journal.

Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma

Sarah E. Johnstone, B. Bernstein, Nicolò Riggi, 2023, Cell genomics.

378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies

G. Demetri, A. Cesne, J. Schellens, 2014 .

Abstract 3810: Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) in vivo

G. Demetri, R. Carlson, E. Baloglu, 2014 .

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

G. Demetri, R. Maki, S. George, 2008, Journal of the National Cancer Institute.

Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).

J. Blay, G. Demetri, A. Cesne, 2010 .

Phase II Study of the Antiangiogenic Agent SU 5416 in Patients with Advanced Soft Tissue Sarcomas

J. Manola, J. Desai, S. Silverman, 2004 .

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

K. Gish, G. Demetri, Ying Huang, 2018, Experimental and Molecular Therapeutics.

Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)

R. Jain, Y. Boucher, G. Demetri, 2012, PloS one.

NCCN Task Force report: gastrointestinal stromal tumor (GIST).

G. Demetri, R. DeMatteo, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).

J. Blay, G. Demetri, R. Maki, 2016 .

Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).

Robin L. Jones, G. Demetri, C. Cleeland, 2016 .

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

G. Demetri, J. Bruix, A. Grothey, 2021, Cancer management and research.

Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST).

J. Blay, G. Demetri, H. Joensuu, 2016 .

Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, M. Bertagnolli, G. Demetri, 2006, Journal of Clinical Oncology.

Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors.

G. Demetri, A. Pappo, L. Rosen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033.

J. Crowley, G. Demetri, C. Blanke, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM).

A. D. Van den Abbeele, S. Silverman, K. Tuncali, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy

J. Desai, G. Demetri, S. George, 2005 .

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Philip S. Yu, Sharon S. Choi, Omar H. Butt, 2023, BMC Cancer.

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)

J. Blay, G. Demetri, I. Ray-Coquard, 2008 .

Erratum: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Concensus Conference of 20-21 March 2004, under the auspices of ESMO (Annals of Oncology (2005) vol. 16 (566-578))

J. Blay, G. Demetri, M. Glabbeke, 2005 .

Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST

G. Demetri, Yoon-Koo Kang, P. Reichardt, 2008 .

Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

B. Spiegelman, E. Winer, G. Demetri, 2003, Breast Cancer Research and Treatment.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

J. Blay, G. Demetri, A. Cesne, 2019, BMC Cancer.

Tales of Personalized Cancer Treatment.

G. Demetri, 2016, Seminars in nephrology.

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.

C. Shapiro, G. Demetri, R. Gelman, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ET‐743: The US experience in sarcomas of soft tissues

G. Demetri, 2002, Anti-cancer drugs.

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

J. Manola, J. Desai, G. Demetri, 2005 .

A new model: physician-patient collaboration in online communities and the clinical practice of oncology.

G. Demetri, H. West, Dave deBronkart, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Therapeutic Innovations in Oncology

G. Demetri, C. Jenkins, 2016 .

Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial

G. Demetri, S. George, C. Devine, 2008 .

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020

G. Demetri, B. Arondekar, M. Duh, 2021, Clinical Cancer Research.

Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, G. Demetri, W. Hayes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

A. Drilon, G. Demetri, T. Wilson, 2022, Clinical Cancer Research.

J. Blay, G. Demetri, P. Casali, 2014 .

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.

A. Drilon, G. Demetri, T. Wilson, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

P. Febbo, M. Ladanyi, G. Demetri, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000

C. Antonescu, G. Demetri, R. Maki, 2005 .

Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment

G. Demetri, E. Baldini, S. George, 2015, Sarcoma.

Two patients with sarcoma. Case 2. Uterine sarcoma.

G. Demetri, G. Blobe, M. Janicek, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

J. Blay, G. Demetri, A. Cesne, 2008 .

NCCN sarcoma practice guidelines. National Comprehensive Cancer Network.

G. Demetri, E. Casper, R. Pollock, 1998, Oncology.

Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.

J. Fletcher, G. Demetri, M. Heinrich, 2015 .

Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort.

P. Catalano, G. Demetri, S. George, 2020 .

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

S. Gabriel, S. Nelson, M. Meyerson, 2007 .

Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.

J. Manola, J. Desai, G. Demetri, 2006, European journal of cancer.

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

A. D. Van den Abbeele, J. Manola, J. Fletcher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033.

K. Owzar, J. Fletcher, G. Demetri, 2014 .

Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.

A. Drilon, G. Demetri, M. Ahn, 2020 .

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

J. Blay, S. Rodenhuis, G. Demetri, 2013 .

Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.

J. Manola, M. Bertagnolli, G. Demetri, 2009, European journal of cancer.

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.

J. Fletcher, G. Demetri, H. Joensuu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterisation Of The Hepatic Safety Profile Of Trabectedin: Pooled Analysis Of 19 Phase II Clinical Trials (CTS) In 1132 Patients With Solid Tumours

J. Blay, G. Demetri, A. Cesne, 2010 .

Expression ofrasOncogenesinCultured HumanCellsAlters theTranscriptional andPosttranscriptio nal Regulation ofCytokine Genes

G. Demetri, B. W. Zenzie, Elizabeth S. PrattII, 1990 .

Dose-escalation study of a second-generation non-ansamycin HSP 90 inhibitor , onalespib ( AT 13387 ) , in combination with imatinib in patients with metastatic gastrointestinal stromal tumour *

G. Demetri, R. Riedel, M. Heinrich, 2022 .

Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study.

G. Demetri, J. Jagannathan, B. Nam, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas

G. Demetri, C. Bedrosian, K. Sankhala, 2005 .

Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

G. Demetri, A. Elias, C. Wheeler, 1992, Blood.

Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.

G. Demetri, J. Griffin, Myra St Amand, 2005, Clinical journal of oncology nursing.

A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.

J. Hodgson, J. Fletcher, G. Demetri, 2014 .

Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule

J. Blay, G. Demetri, A. Cesne, 2001 .

Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies 1

Jeffrey W. Clark, A. Fischman, G. Demetri, 2001 .

Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors.

J. Blay, G. Demetri, R. Maki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

J. Fletcher, G. Demetri, M. Heinrich, 2008, The Journal of pathology.

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.

J. Blay, G. Demetri, P. Rutkowski, 2010 .

Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).

C. Paweletz, V. Velculescu, J. Fletcher, 2018 .

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

Robin L. Jones, B. Monk, G. Demetri, 2021, Cancer medicine.

Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy

G. Demetri, S. Schuetze, M. Mehren, 2004 .

AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results.

J. Desai, G. Demetri, A. Tolcher, 2010 .

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

G. Demetri, H. Joensuu, M. Heinrich, 2004, Blood.

Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

G. Demetri, Q. Zhang, B. Eisenberg, 2012, Annals of Surgical Oncology.

Sunitinib treatment of pediatric metastatic GIST after failure of imatinib.

G. Demetri, C. Corless, C. Garrett, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor

J. Fletcher, G. Demetri, S. George, 2006 .

383 POSTER A Phase I Study of dasatinib, a Src and multi-kinase inhibitor, in patients (pts) with GIST and other solid tumors

G. Demetri, P. LoRusso, V. Brunton, 2006 .

A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).

J. Blay, G. Demetri, M. von Mehren, 2006, Journal of Clinical Oncology.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass.

G. Demetri, C. Fletcher, Ross L. Titton, 2004, The New England journal of medicine.

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

G. Demetri, R. Motzer, B. Houk, 2010, Cancer Chemotherapy and Pharmacology.

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

J. Fletcher, G. Demetri, M. Heinrich, 2008, The Journal of pathology.

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

P. Jänne, G. Demetri, N. Gray, 2010, Cancer research.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Jeffrey W. Clark, M. Ladanyi, C. Antonescu, 2010, The New England journal of medicine.

Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence

J. Fletcher, G. Demetri, W. Ou, 2019, Oncogene.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

A. D. Van den Abbeele, J. Manola, J. Fletcher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Major response to imatinib mesylate in KIT-mutated melanoma.

A. D. Van den Abbeele, G. Demetri, F. Hodi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thrombopoietin: Basic Biology and Clinical Effects

G. Demetri, C. Begley, John A. Glaspy, 2000 .

A phase 1 study of efatutazone, an oral peroxisome proliferator‐activated receptor gamma agonist, administered to patients with advanced malignancies

G. Demetri, J. Marshall, M. Pishvaian, 2012, Cancer.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

J. Blay, G. Demetri, A. Cesne, 2016, The Lancet.

Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.

G. Demetri, G. Gordon, E. Rowinsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Jessica M. Silvaggi, B. Spiegelman, R. Weissleder, 2008, Clinical Cancer Research.

Regression of Drug-resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin Cancer Therapy: Preclinical

Jessica M. Silvaggi, G. Demetri, R. Padera, 2022 .

A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS)

G. Demetri, E. Rowinsky, L. Baker, 2005 .

Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).

J. Blay, G. Demetri, A. Santoro, 2012 .

Preclinical modeling of leiomyosarcoma identifies susceptibility to transcriptional CDK inhibitors through antagonism of E2F-driven oncogenic gene expression.

A. Letai, B. Crompton, G. Demetri, 2022, Clinical Cancer Research.

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

J. Blay, G. Demetri, B. Bui, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.

J. Blay, G. Demetri, A. Cesne, 2012 .

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

G. Demetri, B. Druker, C. Arteaga, 2015, Circulation.

OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease.

G. Demetri, 2003, European journal of cancer.

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.

G. Demetri, K. Ganjoo, S. George, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gastrointestinal stromal tumors (GISTs)

S. Ashley, G. Demetri, Mandeep S. Saund, 2004, Current opinion in gastroenterology.

Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors

Su-Chun Cheng, J. Fletcher, G. Demetri, 2005 .

Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.

J. Fletcher, G. Demetri, C. Raut, 2016 .

The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.

G. Demetri, 1994, Hematology/oncology clinics of North America.